Ball BJ, Arslan S, Koller P, Ngo D, et al. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma 2022 Sep 10:1-5. doi: 10.1080/10428194.2022.2116934.
PMID: 36089918